Popular Articles

AARP Presses Lawmakers To Support Long Term Care
AARP Executive Vice President Nancy LeaMond released

CFIA And USDA Revise Potato Cyst Nematode Guidelines
The Canadian Food Inspection Agency (CFIA) and the United States Department of Agriculture (USDA) today announced revised guidelines for potato cyst nematode (PCN) that will allow continued trade of seed potatoes between the two countries. While PCN does not pose a risk to human health, it is recognized internationally as a destructive plant pest of economic importance and, therefore, a quarantine pest for the United States and Canada.
News of the day
Ambulance Of Tomorrow Unveiled
"Smart Pod", ideas for the ambulance of the future - was unveiled to the NHS and the healthcare industry at the NHS Innovation Expo in London.
Oncology

Cobalis Corporation Is Awarded Two New International Patents In Canada And Mexico For Its Revolutionary Anti-Allergy Relief Product PreHistin(R)

Cobalis Corporation (OTC:CLSC) was recently awarded two additional International Patents in Canada and Mexico and has a patent pending application in Japan. PreHistin® is patented, safe for long-term daily use and available without a prescription. It is available in a cherry flavored, all natural, proprietary cyanocobalamin (vitamin B12) sub-lingual lozenge that is taken twice daily to regulate allergy sufferers" response to both indoor and outdoor allergens with daily and year round usage. Cobalis representatives indicate, "Cyanocobalamin has an excellent safety record, has been safety accepted by the US FDA, and has no upper dosage limits or contra-drug indications. For over 50 years the FDA has approved cyanocobalamin as a drug for anemia. Each PreHistin® lozenge contains 3.3mg Cyanocobalamin. For less than $1.00 per day, twice daily use of PreHistin® has been clinically shown to significantly increase serum vitamin B12 levels, making PreHistin® a cost effective and convenient alternative to other Vitamin B12 therapies, including needle injections." Cobalis Board Member, Dr. Kevin Prendiville states, "These new patents, in addition to the European Union, Australian and two U.S. patents further strengthen the value and assets of Cobalis Corporation intellectual properties. Furthermore, PreHistin®"s box, labeling and related box insert have been approved by DSHEA (Dietary Supplement Health and Education Act) regulation attorneys." About Cobalis Corp-Prehistin® "The World"s First Pre-Histamine" Headquartered in Irvine, California, Cobalis Corp. is an over the counter pharmaceutical and nutraceutical company. Its flagship product, PreHistin® is designed to prevent the primary causes of airborne allergies. PreHistin®, "The World"s First Pre-Histamine" is the only Phase III clinically tested sublingual product fully patented for long term and daily use without a prescription to help relieve allergy sufferers of both indoor and outdoor allergens. PreHistin® is manufactured by Monarch Nutraceutical Inc., a division of Nutraceutical Corporation in Ogden Utah. Nutraceutical Corp. (NUTR) was the original manufacturer of PreHistin® under the name Alleratin, which was distributed to thousands of allergy suffers without cost for compassionate use. Additional PreHistin® manufacturing partners include Marrs Printing, Walnut, CA and Merical Inc, Anaheim, CA. Domestic and international PreHistin® orders are currently fulfilled by International Sales and Marketing (ISM), Newark, NJ. For product information and ordering please visit at http://www.PreHistin.comor call toll free 1-877-4POLLEN. For additional company information please visit their website at http://www.Cobalis.com Cobalis Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):